Peer-Review Report of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7063)
All Articles published online
|
Publishing Process of This Article
|
Dec 27, 2021 (publication date) through Mar 25, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Di Giorgio A, Tulone A, Nicastro E, Norsa L, Sonzogni A, D'Antiga L. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience. World J Hepatol 2021; 13(12): 2113-2127 [PMID: 35070012 DOI: 10.4254/wjh.v13.i12.2113] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Di Giorgio A, Tulone A, Nicastro E, Norsa L, Sonzogni A, D'Antiga L. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience. World J Hepatol 2021; 13(12): 2113-2127 [PMID: 35070012 DOI: 10.4254/wjh.v13.i12.2113] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i12/2113.htm |
| Number | Citing Articles |
| 1 |
Alessandra Elvevi, Alice Laffusa, Camilla Gallo, Pietro Invernizzi, Sara Massironi. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. Cells 2023; 12(3): 370 doi: 10.3390/cells12030370
|
| 2 |
Gül Çirkin, Selma Aydemir, Burcu Açıkgöz, Aslı Çelik, Yunus Güler, Müge Kiray, Başak Baykara, Ener Çağrı Dinleyici, Yeşim Öztürk. Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. International Journal of Molecular Sciences 2025; 26(17): 8616 doi: 10.3390/ijms26178616
|
| 3 |
Cristo Yared Pérez Martin, José Ramón Alberto Alonso, Jenifer González Chávez, María Pilar Díaz Ruiz, Marta Suárez González, Javier Merino Alonso. [Translated article] Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease. Farmacia Hospitalaria 2023; 47(6): T297 doi: 10.1016/j.farma.2023.09.005
|
| 4 |
Eva Vlčková, Katarína Mitrová. Sclerosing cholangitis in children with inflammatory bowel disease. Česko-slovenská pediatrie 2023; 78(3): 182 doi: 10.55095/CSPediatrie2023/025
|
| 5 |
Kai Markus Schneider, Martin Kummen, Palak J. Trivedi, Johannes R. Hov. Role of microbiome in autoimmune liver diseases. Hepatology 2024; 80(4): 965 doi: 10.1097/HEP.0000000000000506
|
| 6 |
Ugo Cucinotta, Valeria Dipasquale, Claire Mayer, Angela Alibrandi, Bénédicte Pigneur, Servane Avril, Chiara Bergamo, Rossella Morello, Frank Rummele, Claudio Romano, Florence Lacaille. Does the SCOPE (Sclerosing Cholangitis Outcomes in PEdiatrics) index effectively predict later liver transplantation in children with sclerosing cholangitis?. Digestive and Liver Disease 2025; 57(6): 1247 doi: 10.1016/j.dld.2025.03.021
|
| 7 |
Kevin M. Johnson, John Grady, Richard Kellermayer, Harland S. Winter, James H. Tabibian, Cynthia W. Buness, Ryan Fischer, Ayesha Shah, Parambir S. Dulai, Amol S. Rangnekar, Leina Alrabadi, Shamita B. Shah, Gerald Holtmann, Laura Räisänen, Peter Lewindon, Ahmad H. Ali. Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forward. Expert Review of Gastroenterology & Hepatology 2026; 20(3): 233 doi: 10.1080/17474124.2026.2635420
|
| 8 |
Cristo Yared Pérez Martin, José Ramón Alberto Alonso, Jenifer González Chávez, María Pilar Díaz Ruiz, Marta Suárez González, Javier Merino Alonso. Vancomicina oral en un paciente pediátrico con colangitis esclerosante primaria y enfermedad inflamatoria intestinal. Farmacia Hospitalaria 2023; 47(6): 297 doi: 10.1016/j.farma.2023.06.015
|
| 9 |
Shanshan Wang, Alisa Farokhian, Bo Shen. Clinical association between inflammatory bowel disease and primary sclerosing cholangitis: what changes after colectomy and liver transplantation?. eGastroenterology 2025; 3(3): e100199 doi: 10.1136/egastro-2025-100199
|
| 10 |
Laura Cristoferi, Daphne D’Amato, Cesare Maino, Davide Bernasconi, Marco Emilio Dinelli, Sergio Maria Ivano Malandrin, Federica Facciotti, Marco Mario Festa, Alessio Gerussi, Emanuela Rossi, Federica Malinverno, Pietro Tettamanti, Marina Elena Cazzaniga, Rocco Corso, Davide Ippolito, Stefania Galimberti, Pietro Invernizzi, Marco Carbone. Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial. BMJ Open 2026; 16(1): e106630 doi: 10.1136/bmjopen-2025-106630
|